Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Prepaid Assets (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Prepaid Assets readings, the most recent being $6.9 million for Q4 2025.

  • On a quarterly basis, Prepaid Assets rose 59.84% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.9 million, a 59.84% increase, with the full-year FY2025 number at $6.9 million, up 59.84% from a year prior.
  • Prepaid Assets hit $6.9 million in Q4 2025 for Avalo Therapeutics, up from $2.1 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $6.9 million in Q4 2025 to a low of $100000.0 in Q1 2024.
  • Median Prepaid Assets over the past 5 years was $1.7 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Prepaid Assets: plummeted 93.85% in 2024 and later surged 1803.0% in 2025.
  • Avalo Therapeutics' Prepaid Assets stood at $2.4 million in 2021, then tumbled by 45.62% to $1.3 million in 2022, then crashed by 61.24% to $500000.0 in 2023, then surged by 765.0% to $4.3 million in 2024, then soared by 59.84% to $6.9 million in 2025.
  • The last three reported values for Prepaid Assets were $6.9 million (Q4 2025), $2.1 million (Q3 2025), and $1.9 million (Q2 2025) per Business Quant data.